FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079711500> ?p ?o ?g. }

• W2079711500 abstract "Sirolimus (SRL, Rapamycin) has been used successfully to inhibit restenosis both in drug eluting stents (DES) and after systemic application. The current study reports on the effects of SRL in various human in vitro/ex vivo models and evaluates the theoretical clinical relevance of the data by SI/MPL- and SI/DES-ratio's. Definition of the SI/MPL-ratio: relation between significant inhibitory effects in vitro/ex vivo and the maximal plasma level after systemic administration in vivo (6.4 ng/ml for SRL). Definition of the SI/DES-ratio: relation between significant inhibitory effects in vitro/ex vivo and the drug concentration in DES (7.5 mg/ml in the ISAR drug-eluting stent platform). Part I of the study investigated in cytoflow studies the effect of SRL (0.01–1000 ng/ml) on TNF-α induced expression of intercellular adhesion molecule 1 (ICAM-1) in human coronary endothelial cells (HCAEC) and human coronary smooth muscle cells (HCMSMC). Part II of the study analysed the effect of SRL (0.01–1000 ng/ml) on cell migration of HCMSMC. In part III, IV, and V of the study ex vivo angioplasty (9 bar) was carried out in a human organ culture model (HOC-model). SRL (50 ng/ml) was added for a period of 21 days, after 21 and 56 days cell proliferation, apoptosis, and neointimal hyperplasia was studied. Expression of ICAM-1 was significantly inhibited both in HCAEC (SRL ≥ 0.01 ng/ml) and HCMSMC (SRL ≥ 10 ng/ml). SRL in concentrations ≥ 0.1 ng/ml significantly inhibited migration of HCMSMC. Cell proliferation and neointimal hyperplasia was inhibited at day 21 and day 56, significance (p < 0.01) was achieved for the inhibitory effect on cell proliferation in the media at day 21. The number of apoptotic cells was always below 1%. SI/MPL-ratio's ≤ 1 (ICAM-1 expression, cell migration) characterize inhibitory effects of SRL that can be theoretically expected both after systemic and local high dose administration, a SI/MPL-ratio of 7.81 (cell proliferation) represents an effect that was achieved with drug concentrations 7.81-times the MPL. SI/DES-ratio's between 10-6 and 10-8 indicate that the described inhibitory effects of SRL have been detected with micro to nano parts of the SRL concentration in the ISAR drug-eluting stent platform. Drug concentrations in DES will be a central issue in the future." @default.
• W2079711500 created "2016-06-24" @default.
• W2079711500 creator A5000153719 @default.
• W2079711500 creator A5007182973 @default.
• W2079711500 creator A5038916521 @default.
• W2079711500 creator A5050487391 @default.
• W2079711500 creator A5051947666 @default.
• W2079711500 creator A5068140450 @default.
• W2079711500 creator A5069831361 @default.
• W2079711500 creator A5072233690 @default.
• W2079711500 creator A5083035834 @default.
• W2079711500 creator A5084593143 @default.
• W2079711500 creator A5087613717 @default.
• W2079711500 date "2007-05-11" @default.
• W2079711500 modified "2023-09-25" @default.
• W2079711500 title "Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratio's" @default.
• W2079711500 cites W1547165466 @default.
• W2079711500 cites W1569514623 @default.
• W2079711500 cites W1640004929 @default.
• W2079711500 cites W1779170284 @default.
• W2079711500 cites W1964319827 @default.
• W2079711500 cites W1968692561 @default.
• W2079711500 cites W1974046965 @default.
• W2079711500 cites W1998004031 @default.
• W2079711500 cites W2004739032 @default.
• W2079711500 cites W2007576777 @default.
• W2079711500 cites W2019488469 @default.
• W2079711500 cites W2020791685 @default.
• W2079711500 cites W2026813388 @default.
• W2079711500 cites W2053467994 @default.
• W2079711500 cites W2057892556 @default.
• W2079711500 cites W2063709836 @default.
• W2079711500 cites W2063810817 @default.
• W2079711500 cites W2067196635 @default.
• W2079711500 cites W2072771705 @default.
• W2079711500 cites W2090221119 @default.
• W2079711500 cites W2104765420 @default.
• W2079711500 cites W2107128368 @default.
• W2079711500 cites W2108989633 @default.
• W2079711500 cites W2110273274 @default.
• W2079711500 cites W2112561553 @default.
• W2079711500 cites W2115973039 @default.
• W2079711500 cites W2143639142 @default.
• W2079711500 cites W2154527891 @default.
• W2079711500 cites W2160290630 @default.
• W2079711500 cites W2160563474 @default.
• W2079711500 cites W2322745866 @default.
• W2079711500 cites W2323954120 @default.
• W2079711500 cites W2394850806 @default.
• W2079711500 cites W2951487912 @default.
• W2079711500 doi "https://doi.org/10.1186/1471-2261-7-15" @default.
• W2079711500 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1878500" @default.
• W2079711500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17498286" @default.
• W2079711500 hasPublicationYear "2007" @default.
• W2079711500 type Work @default.
• W2079711500 sameAs 2079711500 @default.
• W2079711500 citedByCount "4" @default.
• W2079711500 countsByYear W20797115002016 @default.
• W2079711500 countsByYear W20797115002022 @default.
• W2079711500 crossrefType "journal-article" @default.
• W2079711500 hasAuthorship W2079711500A5000153719 @default.
• W2079711500 hasAuthorship W2079711500A5007182973 @default.
• W2079711500 hasAuthorship W2079711500A5038916521 @default.
• W2079711500 hasAuthorship W2079711500A5050487391 @default.
• W2079711500 hasAuthorship W2079711500A5051947666 @default.
• W2079711500 hasAuthorship W2079711500A5068140450 @default.
• W2079711500 hasAuthorship W2079711500A5069831361 @default.
• W2079711500 hasAuthorship W2079711500A5072233690 @default.
• W2079711500 hasAuthorship W2079711500A5083035834 @default.
• W2079711500 hasAuthorship W2079711500A5084593143 @default.
• W2079711500 hasAuthorship W2079711500A5087613717 @default.
• W2079711500 hasBestOaLocation W20797115001 @default.
• W2079711500 hasConcept C126322002 @default.
• W2079711500 hasConcept C150903083 @default.
• W2079711500 hasConcept C185592680 @default.
• W2079711500 hasConcept C202751555 @default.
• W2079711500 hasConcept C207001950 @default.
• W2079711500 hasConcept C26291073 @default.
• W2079711500 hasConcept C2777339539 @default.
• W2079711500 hasConcept C2777921159 @default.
• W2079711500 hasConcept C2778283817 @default.
• W2079711500 hasConcept C2778583881 @default.
• W2079711500 hasConcept C55493867 @default.
• W2079711500 hasConcept C71924100 @default.
• W2079711500 hasConcept C86803240 @default.
• W2079711500 hasConcept C98274493 @default.
• W2079711500 hasConceptScore W2079711500C126322002 @default.
• W2079711500 hasConceptScore W2079711500C150903083 @default.
• W2079711500 hasConceptScore W2079711500C185592680 @default.
• W2079711500 hasConceptScore W2079711500C202751555 @default.
• W2079711500 hasConceptScore W2079711500C207001950 @default.
• W2079711500 hasConceptScore W2079711500C26291073 @default.
• W2079711500 hasConceptScore W2079711500C2777339539 @default.
• W2079711500 hasConceptScore W2079711500C2777921159 @default.
• W2079711500 hasConceptScore W2079711500C2778283817 @default.
• W2079711500 hasConceptScore W2079711500C2778583881 @default.
• W2079711500 hasConceptScore W2079711500C55493867 @default.
• W2079711500 hasConceptScore W2079711500C71924100 @default.
• W2079711500 hasConceptScore W2079711500C86803240 @default.
• W2079711500 hasConceptScore W2079711500C98274493 @default.

• next